Reversing tumor immunosuppressive microenvironment via targeting codelivery of CpG ODNs/PD-L1 peptide antagonists to

Min Zhang1, Zhou Fang1, Haitao Zhang1

  • 1Department of Biopharmacy, Shanghai Ocean University, Hucheng Ring Road, Shanghai 201306, China.

Insights

This study developed a novel mannose-modified liposome system (HA/M-Lipo CpG-P) for co-delivering CpG oligonucleotides and PD-L1 peptides. This approach effectively reversed tumor immunosuppression and enhanced anti-tumor immunity.

Area of Science:

  • Biomedical Engineering
  • Immunology
  • Nanotechnology

Background:

  • Tumor immunosuppressive microenvironments hinder effective anti-tumor immunity.
  • Immune checkpoint blockade therapies show promise but can be limited by delivery challenges.

Purpose of the Study:

  • To construct a mannose-modified liposome system for co-delivery of CpG ODNs and PD-L1 antagonistic peptides.
  • To enhance systemic circulation stability and tumor tissue accumulation for improved anti-tumor immune effects.

Main Methods:

  • Development of hyaluronic acid (HA)-coated, mannose-modified liposomes (HA/M-Lipo) for co-delivery of CpG ODNs and PD-L1 antagonistic peptides (P).
  • Investigated HA hydrolysis by hyaluronidase and peptide release mediated by matrix metalloproteinases (MMPs).
  • Utilized mannose-modified liposomes for macrophage recognition and intracellular CpG ODN delivery.

Main Results:

  • HA/M-Lipo CpG-P complexes successfully reversed M2-type macrophages to M1 in the tumor microenvironment.
  • Demonstrated activation of anti-tumor immune cells and significant inhibition of tumor growth.
  • Showed superior tumor inhibitory effects compared to monotherapy or single-component delivery systems.

Conclusions:

  • HA/M-Lipo CpG-P complexes represent a promising co-delivery strategy for targeting tumors.
  • This system effectively improves anti-tumor effects by modulating the tumor microenvironment and enhancing immune checkpoint blockade efficacy.

Related Concept Videos